Received Jun 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 59PX7 | IM / LA |
redness; swelling; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 58-year-old female patient who received Herpes zoster (Shingrix) (batch number 59PX7 with expiry date 26-AUG-2027) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix (intramuscular, left arm). On an unknown date, 24 hrs after receiving Shingrix, the patient experienced injection site erythema (Verbatim: redness) and injection site swelling (Verbatim: swelling). The patient was treated with diphenhydramine. The outcome of the injection site erythema and injection site swelling were resolved. It was unknown if the reporter considered the injection site erythema and injection site swelling to be related to Shingrix. Additional Information: GSK Receipt Date: 29-MAY-2026 The patient had developed a pronounced local reaction consisting of redness and swelling over an area of approximately 3 cross 3 inches in diameter in response to this vaccine. The reporter had stated that the localized reaction had developed within 24 hours of the injection and that it had not been an immediate reaction. She had further reported that the reaction had resolved with the use of a few doses of diphenhydramine and that the patient had not sought medical attention.